Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
Leu133, monoclonal
Application:
ICC, WB
Citations:
6
biological source
mouse
conjugate
unconjugated
antibody form
tissue culture supernatant
antibody product type
primary antibodies
clone
Leu133, monoclonal
form
buffered aqueous solution
mol wt
antigen ~43 kDa
species reactivity
monkey, human, mouse
technique(s)
immunocytochemistry: suitable, western blot: 1:8000-1:16,000 using human Ramos cell extracts
isotype
IgM
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... LPXN(9404)
mouse ... Lpxn(107321)
General description
Monoclonal Anti-Leupaxin (mouse IgM isotype) is derived from the hybridoma Leu133 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a peptide corresponding to a sequence at the N-terminus human Leupaxin conjugated to KLH. Leupaxin is a LIM (Lin11, Isl-1 and Mec-3) domain phosphotyrosine protein preferentially expressed in lymphoid tissues and hematopoietic cells. Leupaxin shares homology with the focal adhesion protein paxillin, in the LIM and LD (leucine/aspartate repeat) protein interaction domains. Leupaxin is expressed in cell types that lack FAK, such as human macrophages.
Immunogen
peptide corresponding to a sequence at the N-terminus human Leupaxin, conjugated to KLH. The corresponding sequence is identical in human leupaxin 1 and 2 isoforms.
Application
Monoclonal Anti-Leupaxin antibody produced in mouse has been used in immunoblotting and immunocytochemistry.
Biochem/physiol Actions
Leupaxin LIM domains have been shown to mediate localization to focal contacts and LD motifs have been implicated in focal adhesion kinase (FAK) and vinculin binding, resulting in the localization of FAK to focal adhesions. Leupaxin and protein tyrosine kinase 2 β (PYK2) are both preferentially expressed in leukocytes where they regulate cell type-specific signaling complex. Leupaxin can form a complex with PYK2 and PTP-PEST in several cell types including monocytes and osteoclasts and in prostate cancer cells. In osteoclasts, leupaxin has been suggested to be a critical nucleating component of the osteoclast podosomal signaling complex in the adhesion zone. Leupaxin is expressed in prostate cancer and is thought to play a role in adhesion and invasion of prostate carcinoma cells.
Physical form
Solution containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Instructions
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells
Sahu SN, et al.
American Journal of Physiology. Cell Physiology, 292(6), C2288-C2296 (2007)
Leupaxin binds to PEST domain tyrosine phosphatase PEP
Watanabe N, et al.
Molecular and Cellular Biochemistry, 269(1), 13-17 (2005)
Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression
Kaulfuss S, et al.
Oncogene, 28(45), 3971-3971 (2009)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SAB4200301-200UL | 04061837725319 |